Everpar Advisors LLC Invests $212,000 in Laboratory Co. of America Holdings (NYSE:LH)

Everpar Advisors LLC bought a new stake in shares of Laboratory Co. of America Holdings (NYSE:LH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 934 shares of the medical research company’s stock, valued at approximately $212,000.

Other institutional investors also recently bought and sold shares of the company. Trust Investment Advisors raised its position in Laboratory Co. of America by 1.8% during the 4th quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock valued at $583,000 after purchasing an additional 46 shares during the last quarter. Atria Wealth Solutions Inc. raised its position in shares of Laboratory Co. of America by 2.8% in the 4th quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock worth $448,000 after acquiring an additional 53 shares in the last quarter. Caprock Group LLC raised its position in shares of Laboratory Co. of America by 1.8% in the 4th quarter. Caprock Group LLC now owns 3,084 shares of the medical research company’s stock worth $701,000 after acquiring an additional 56 shares in the last quarter. Arjuna Capital raised its position in shares of Laboratory Co. of America by 3.2% in the 3rd quarter. Arjuna Capital now owns 1,819 shares of the medical research company’s stock worth $366,000 after acquiring an additional 57 shares in the last quarter. Finally, Greenleaf Trust raised its position in shares of Laboratory Co. of America by 2.5% in the 3rd quarter. Greenleaf Trust now owns 2,559 shares of the medical research company’s stock worth $514,000 after acquiring an additional 62 shares in the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Laboratory Co. of America Stock Up 0.1 %

NYSE LH opened at $201.61 on Thursday. Laboratory Co. of America Holdings has a 52 week low of $174.20 and a 52 week high of $234.09. The firm has a market capitalization of $17.00 billion, a price-to-earnings ratio of 40.57, a PEG ratio of 1.51 and a beta of 1.02. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. The company has a fifty day moving average of $209.55 and a two-hundred day moving average of $214.89.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business had revenue of $3.18 billion during the quarter, compared to the consensus estimate of $3.12 billion. During the same quarter last year, the firm earned $3.82 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. On average, analysts predict that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, May 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.43%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.

Analyst Ratings Changes

Several research analysts have recently issued reports on LH shares. Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research report on Monday, March 25th. SVB Leerink initiated coverage on Laboratory Co. of America in a research note on Monday, February 26th. They set an “outperform” rating and a $260.00 target price on the stock. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. Robert W. Baird decreased their target price on Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. Finally, Evercore ISI assumed coverage on Laboratory Co. of America in a report on Friday, February 9th. They issued an “in-line” rating and a $240.00 target price on the stock. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $243.14.

Insider Buying and Selling at Laboratory Co. of America

In related news, Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $200.10, for a total value of $50,025.00. Following the completion of the sale, the director now owns 15,722 shares in the company, valued at $3,145,972.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CMO Amy B. Summy sold 227 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $218.45, for a total value of $49,588.15. Following the completion of the sale, the chief marketing officer now owns 3,859 shares in the company, valued at $842,998.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 250 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $200.10, for a total value of $50,025.00. Following the sale, the director now owns 15,722 shares of the company’s stock, valued at approximately $3,145,972.20. The disclosure for this sale can be found here. Insiders sold 56,985 shares of company stock worth $12,302,964 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).